Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

So it was that Saturday 1st July was a busy day. Organon and Samsung Bioepsis were first to launch biosimilar Hadlima (adalimumab-bwwd) that day, at the sale price of $1,038 per carton containing ...

Now, Samsung Bioepis and marketing partner Organon have the clinical data they need to get their Hadlima biosimilar approved as an interchangeable option and seek a leg-up in the competitive ...

In its place, the PBM included the Humira-referenced biosimilars Hyrimoz, Hadlima and adalimumab-fkjp (an unbranded product). Hyrimoz appears to be the most favored biosimilar. While removal of ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

A majority of biosimilar gains are due to Hyrimoz (adalimumab-adaz) and Hadlima (adalimumab-bwwd). These biosimilars have provided the market with diverse WAC pricing options that offer reduced ...

The South Korean drugmaker added that Hyrimoz and Hadlima, Humira biosimilars marketed by CVS Health (CVS)/Sandoz (SDXNY) (OTCQX:SDZXF) and Organon (OGN)/Samsung Bioepis, respectively, have led to ...

Women's health grew 5% ex-FX, while biosimilars increased by 12% ex-FX ... while volume growth added $415 million, led by Hadlima, Emgality, and Nexplanon. Free cash flow before one-time costs ...